Articles

Global cancer burden attributable to excess body weight, 1990 to 2021, decomposed by population size, aging, and epidemiological change

Xiaoru Feng, Ruoqian Li, and Hang Yi. Obesity. 2025 Mar;33(3):567-577

The objective of this study was to estimate cancer burden attributable to excess body weight (EBW) and identify its main source. The incidence of 11 EBW-related cancers has increased from 1990 to 2021. Later-born cohorts and older age groups had higher cancer incidence rates. High BMI was the top contributor to changes... Read More

24 Mar, 2026

A global health crisis in young adults: 30-Year trends in high BMI-related early-onset cancer mortality

Rupayan Kundu , Rishabh Kundu , Sudipto Mukherjee. Ann Epidemiol. 114:7-11. 2026

 Early-onset cancer (EOC), occurring in individuals aged 15-49 years, is a growing global health concern. High body mass index (BMI) is an established modifiable risk factor contributing to cancer morbidity and mortality. In 2021, 23,078 EOC deaths related to high BMI occurred, accounting for 2.33 % of global EOC morta... Read More

24 Mar, 2026

Global and regional burden of breast cancer attributable to high BMI, 1990–2036: A comprehensive analysis

Yuzhou Cai , Ying Ye , Jingxian Qian. Public Health. 2025 May:242:340-351

This study aimed to assess global, regional, and national trends in breast cancer burden attributable to high body mass index (BMI) from 1990 to 2021 and provide projections up to 2036 using data from the Global Burden of Disease (GBD) 2021 study. In 2021, high BMI contributed to 44,707 breast cancer deaths and 1,041,3... Read More

24 Mar, 2026

Burden of colorectal cancer attributable to high body-mass index in 204 countries and territories, 1990–2021: Results from the Global Burden of Disease Study 2021

Qiuxia Zhang , Jia Feng , Zhijie Xu, et al. Public Health. 2025 May:242:388-398

A strong association between high Body Mass Index (BMI) and Colorectal Cancer (CRC) has been well established. This study aims to examine and analyze the burden of CRC linked to high BMI at global, regional, and national levels from 1990 to 2021.  In 2021, the global deaths and DALYs of CRC attributed to high BMI were ... Read More

24 Mar, 2026

Burden of cancer attributable to high body mass index: A systematic analysis of the Global Burden of Disease Study 2021

Gisella Figlioli , Daniele Piovani , Andreas G Tsantes et al. Clinical Nutrition 48 (2025) 144e152

High body mass index (BMI) is a well-established cancer risk factor. Reliable, updated data are essential for guiding public health policies and designing effective interventions to reduce the cancer burden associated with high BMI. In 2021, cancer attributable to high BMI resulted in 356.74 thousand deaths and 8.89 mi... Read More

24 Mar, 2026

The Lancet Commission on prostate cancer: planning for the surge in cases

Nicholas D James, Ian Tannock, James N'Dow, et al. Lancet. 2024 Apr 27;403(10437):1683-1722

Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 based on data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise ... Read More

24 Mar, 2026

Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update

Elizabeth J Schafer, Mathieu Laversanne , Hyuna Sung , et al. Eur Urol. 2025 Mar;87(3):302-313

Our aim was to examine worldwide patterns and trends for prostate cancer (PC) incidence and mortality using high-quality, up-to-date, population-based data.  Estimated PC rates across regions in 2022 varied 13-fold for incidence and 9.5-fold for mortality. The highest incidence rates were in Australia/New Zealand, Nort... Read More

24 Mar, 2026

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

Julio Garcia-Aguilar 1, Sujata Patil 2, Marc J Gollub 3, et al. J Clin Oncol. 2022 Aug 10;40(23):2546-2556

In this prospective, randomized phase II trial, we assessed the outcomes of 324 patients with stage II or III rectal adenocarcinoma treated with induction chemotherapy followed by chemoradiotherapy (INCT-CRT) or chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT) and either total mesorectal excision (TM... Read More

24 Mar, 2026

The triple effect of colorectal cancer screening: reducing deaths, government spending, and mortality disparities

Pedro Nascimento de Lima , Lillian Bartholomew , Folasade P May, et al. J Natl Cancer Inst. 2026 Feb 1;118(2):360-363

Colorectal cancer (CRC) screening accounts for over 60% of cancer screening costs in the United States, prompting recurrent debates about its value. Yet CRC screening remains the main tool to curb overall CRC incidence, mortality, and disparities that affect Black Americans. Using the race-specific CRC-SPIN microsimula... Read More

24 Mar, 2026

Comparing cohort and period trends of early-onset colorectal cancer: a global analysis

Jianjiu Chen, and Wan Yang. JNCI Cancer Spectrum, 2024, 8(4), pkae052

 Incidence of early-onset colorectal cancer (CRC) has increased globally in recent decades. We examined early-onset CRC incidence trends worldwide for potential cohort effects, defined as changes associated with time of birth (eg, early-life exposure to carcinogens), and period effects, defined as changes associated wi... Read More

24 Mar, 2026